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Abstract
In spite of recent advances with experiments on animal models, strongyloidiasis, an infection caused
by the nematode parasite Strongyloides stercoralis, has still been an elusive disease. Though endemic
in some developing countries, strongyloidiasis still poses a threat to the developed world. Due to
the peculiar but characteristic features of autoinfection, hyperinfection syndrome involving only
pulmonary and gastrointestinal systems, and disseminated infection with involvement of other
organs, strongyloidiasis needs special attention by the physician, especially one serving patients in
areas endemic for strongyloidiasis. Strongyloidiasis can occur without any symptoms, or as a
potentially fatal hyperinfection or disseminated infection. Th2 cell-mediated immunity, humoral
immunity and mucosal immunity have been shown to have protective effects against this parasitic
infection especially in animal models. Any factors that suppress these mechanisms (such as
intercurrent immune suppression or glucocorticoid therapy) could potentially trigger
hyperinfection or disseminated infection which could be fatal. Even with the recent advances in
laboratory tests, strongyloidiasis is still difficult to diagnose. But once diagnosed, the disease can be
treated effectively with antihelminthic drugs like Ivermectin. This review article summarizes a case
of strongyloidiasis and various aspects of strongyloidiasis, with emphasis on epidemiology, life cycle
of Strongyloides stercoralis, clinical manifestations of the disease, corticosteroids and strongyloidiasis,
diagnostic aspects of the disease, various host defense pathways against strongyloidiasis, and
available treatment options.
Background
In United States, strongyloidiasis is the most important
nematode infection in humans with a tendency towards
chronic persistent infection and with special characteristic
features of autoinfection, hyperinfection involving pul-
monary and gastrointestinal systems, and disseminated
infection involving other organs [1-4]. Strongyloidiasis is
caused by a soil dwelling nematode helminth, Strongy-
loides stercoralis. This helminth resides in the small intes-
tine of the human host. There is another species of same
genus, Strongyloides fuelleborni that can also cause human
infection but is mostly seen in African countries [4].
Infection with Strongyloides stercoralis was first reported in
the year 1876 in French soldiers working in Vietnam [4].
It took nearly 50 years for the complete elucidation of the
complex life cycle after the discovery of the parasite [4]
because of the rare and characteristic feature of autoinfec-
tion that occurs in the life cycle. Strongyloidiasis was first
described by Fulleborn in 1926 [5]. First reports of dis-
seminated infection or hyperinfection date back to 1966
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when Cruz et al., and Rogers et al., independently docu-
mented the occurrence of fatal strongyloidiasis with
immunosuppression [6,7].
Though many advances have been made in the diagnosis
and treatment of strongyloidiasis, it still prevails as one of
the elusive diseases to tackle in the present day world.
Strongyloidiasis may have a spectrum of manifestations
ranging from the most common asymptomatic disease to
potentially life threatening hyperinfection syndrome and
disseminated disease. The patients, if symptomatic,
present with pulmonary and gastrointestinal symptoms.
Most of them are found to have strongyloidiasis after a
laboratory work up reveals an incidental finding of eosi-
nophilia. This review article documents a case report with
symptoms along with review of the epidemiology, biol-
ogy of strongyloidiasis, clinical manifestations of the dis-
ease including hyperinfection syndrome, effect of
systemic corticosteroids on strongyloidiasis, diagnostic
aspects of the disease, various pathophysiological mecha-
nisms and host defense pathways regulating strongyloi-
diasis, and different options available to treat the
infection.
Case report
A 77 year old male veteran with past medical history sig-
nificant for chronic obstructive pulmonary disease, coro-
nary artery disease status post coronary artery bypass graft,
dyslipidemia, hypertension, and gastro esophageal reflux
disease was found to have an incidental eosinophilia with
12.4% eosinophils (absolute eosinophil count of 800
cells/mm3). He reported morning cough with small
amounts of thick mucus. He denied any epistaxis, diffi-
culty in breathing, abdominal pain, diarrhea and consti-
pation. He had lived in North East Tennessee for almost
30 yrs. He was an ex-smoker but had ceased to smoke
almost 30 years ago. On examination, he was an obese
male with periorbital edema. Auscultation demonstrated
a bruit just above the left sternoclavicular joint, but his
chest was clear to auscultation. A midline scar consistent
with previous coronary bypass grafting was seen. The rest
of the examination was essentially benign.
Due to eosinophilia, a complete evaluation was carried
out. Serological tests for strongyloidiasis were strongly
positive with antibody titer of 12.2 (Normal titer < 1.0).
Total serum levels of IgE and IgA were within-normal lim-
its at 130 IU/mL and 243 mg/dL respectively and no
Strongyloides stercoralis larvae or eggs were found in the
stools as shown in the Table 1. He was given one dose of
ivermectin (200 micrograms/kilogram) and the repeat
labs, a month later, showed improved eosinophil percent-
age at 5.6% with a drop in the eosinophil count to 400
cells/mm3 along with drop in the strongyloid antibody
titer to 6.76 (Normal titer < 1.0) as shown in the Table 1.
Three months after treatment, his respiratory symptoms
improved and one more dose of ivermectin (200 micro-
grams/Kg) was given for still elevated strongyloid anti-
body titer of 6.97 (normal titer < 1.0). Repeat labs, 4
months after the second treatment with ivermectin,
showed decreased strongyloid antibody titer to 5.0 (nor-
mal titer < 1.0) with no eosinophilia and thus indicating
a positive response to treatment (Table 1).
This is a case of mildly symptomatic chronic strongyloi-
diasis with very few respiratory symptoms consisting of
morning cough with small amounts of thick sputum, pos-
itive strongyloid antibody in the serum and negative lar-
vae or eggs in the stool samples. This case also
demonstrates the effectiveness of ivermectin in the treat-
ment of strongyloidiasis.
Epidemiology
Though parasitic infections are rare in the developed
world, sporadic cases of strongyloidiasis, toxocariasis, and
giardiasis happen especially in the endemic areas. Physi-
cians should be aware of the endemic areas for strongyloi-
diasis because of difficulty in diagnosis and high potential
for fatal complications [2]. The parasite is mostly confined
to the tropics and subtropics infecting about 100 million
people in about 70 countries [4]. It is endemic in South-
ern, Eastern, and Central Europe, Islands of the Carib-
bean, Latin America, Sub-Saharan Africa and Southeast
Asia [1,4]. In non-endemic regions of the world, it is diag-
nosed in the prisoners of war (POWs) of World War II and
immigrants from endemic countries [8]. In the United
States, the infection is more prevalent in the Appalachian
region mainly Eastern Kentucky and rural Tennessee with
a prevalence of 4% and 2.5–3% respectively [1]. Males,
people of white race, residents of chronic care institutions
[9], and people working with soil (such as persons
employed in coal mines and farms) are at the greatest risk
of acquiring this disease [10]. A strong association is
noted between strongyloidiasis and concurrent immuno-
suppressive disorders such as HTLV-1 (Human T-cell Lym-
photropic Virus – 1) or HIV (Human Immunodeficiency
Virus) infection and hematological malignancies [11-13].
Biology of Strongyloidiasis
The life cycle of Strongyloides stercoralis is distributed
between the free-living and parasitic cycles [10,14].
Strongyloides stercoralis is a soil dwelling nematode and
may take one of the two cycles depending on the prevalent
conditions and turns parasitic in adverse conditions [10].
The free-living cycle begins with the passage of the rhabdi-
tiform larvae in the stool, which, on reaching the soil,
molt under favorable conditions to become adult free liv-
ing worms. These worms reproduce sexually and produce
rhabditiform larvae in turn, which then molt into filari-
form larvae. The latter forms infect the human host orClinical and Molecular Allergy 2006, 4:8 http://www.clinicalmolecularallergy.com/content/4/1/8
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develop into free living adult forms and continue the free
living cycle as shown in the Figure 1[10,14].
In the parasitic cycle, the rhabditiform larvae once passed
in the stool molt only twice and develop into filariform
larvae, which are infective to humans. When a susceptible
host is available, the infective filariform larvae penetrate
the intact skin, travel to the blood stream via subcutane-
ous lymphatics, and reach the pulmonary circulation.
Here they penetrate the alveolar membrane to become air
borne, ascend the tracheobronchial tree, are swallowed by
the host, reach the small intestine, molt twice more to
become adult parthenogenetic females. The females then
shed eggs which become rhabditiform larvae and are
passed out in the stools, to continue the cycle as shown in
the Figure 1[10,14].
Autoinfection is the one of the important characteristic
features of the life cycle of Strongyloides stercoralis. The var-
ious life cycle changes in the case of autoinfection are: the
rhabditiform larvae instead of being shed in the stool
molt twice in the body of the host (mainly in the intes-
tine) to become filariform larvae that then penetrate the
intestinal wall or perianal skin and reach different organs
of the body leading to hyperinfection syndrome, if limited
to respiratory and gastrointestinal tracts or disseminated
infection with involvement of other organ systems.
Clinical manifestations of Strongyloidiasis
Strongyloidiasis can manifest in a wide spectrum of clini-
cal features ranging from asymptomatic disease, disease
with mild initial symptoms, disease with chronic symp-
toms and acute exacerbation with hyperinfection or dis-
semination of larvae involving respiratory and
gastrointestinal systems or multiple organ systems respec-
tively. Though fatal hyperinfection or dissemination can
occur, asymptomatic strongyloidiasis is the most com-
mon form of the disease [1,10]. The various clinical man-
ifestations are shown in the Table 2.
1. Initial (acute) manifestations
The initial symptoms happen soon after the entry of the
infective filariform larvae into the human host from its
extraintestinal migration in the host. Though the acute
initial manifestations are not well described [15], the fol-
lowing symptoms are noted in some human infections:
serpiginous urticarial rash at the site of entry of the filari-
form larvae mostly in the legs [1,10,15], cough and tra-
cheal irritation mimicking bronchitis from migration of
the larvae through the lungs [10], abdominal cramping
with bloating, watery diarrhea and sometimes constipa-
tion due to lodging of the larvae and maturation into
adult females in the small intestine of the host [10,16-18].
In fact, the most common complaint noted was abdomi-
nal bloating [17,18]. As these initial manifestations are
vague and mimic multiple other diseases, they are often
Table 1: Laboratory Findings of Case Report
Lab Finding Before Rx One Month After 1stRx Four Months After 2ndRx§
Sodium (mEq/L) 146 142 140
Potassium (mEq/L) 4.5 5.3 4.3
Chloride (mEq/L) 105 102 106
Carbon Dioxide (mEq/L) 28 29 27
Glucose (mg/dL) 93 107 93
Blood Urea Nitrogen (mg/dL) 18 20 17
Creatinine (mg/dL) 1.1 1.3 1.3
Calcium (mg/dL) 9.1 9.3 8.9
Albumin (g/dL) 4.1 3.9 *
Total Protein (g/dL) 7.8 7.5 *
Alkaline Phosphatase (U/L) 74 75 *
SGPT (U/L) 18 14 *
SGOT (U/L) 18 21 *
Eosinophils (%) 12.4 5.9 5.2
Absolute Eosinophil Count (cells/
mm3)
800 400 300
Strongyloid Antibody by ELISA 
(Index)
12.20 6.76 5.0
IgE (IU/mL) 130 * *
IgA (mg/dL) 243 * *
S. stercoralis Larvae/Eggs in Sputum 
and Stools
Negative Negative *
*, Not available; Rx, Treatment with Ivermectin; SGPT, Serum Glutamic-Pyruvic Transaminase; SGOT, Serum Glutamine-Oxaloacetic 
Transaminase;
IgE, Immunoglobulin E; IgA, Immunoglobulin A; §, Second treatment with ivermectin is given 3 months after the first treatment;Clinical and Molecular Allergy 2006, 4:8 http://www.clinicalmolecularallergy.com/content/4/1/8
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misdiagnosed and treated symptomatically with the host
still harboring the parasite leading to a chronic state of the
disease.
2. Chronic manifestations
Even though the chronic form of strongyloidiasis is
asymptomatic in most cases, mild symptoms involving
pulmonary and gastrointestinal systems can happen
[10,19]. The various chronic manifestations include nau-
sea, vomiting, epigastric pain with tenderness, intermit-
tent vomiting, diarrhea, constipation, weight loss,
asthma-like symptoms, urticaria and distinctive larva cur-
rens rash from the subcutaneous migration of larvae
[1,10,20-26]. During the asymptomatic stage, the only
clinical finding could be eosinophilia [1,10]. Unless phy-
sicians have high index of suspicion based on various fac-
tors like residence in endemic areas or World War II
veterans, there is a high likelihood of misdiagnosis. This
requires physicians in the endemic areas to be more
aggressive in their investigational workup for eosi-
nophilia. This idea is exemplified by the patient described
earlier.
3. Hyperinfection syndrome
Immunosuppression, either iatrogenic (for example, use
of systemic corticosteroids for chronic obstructive pulmo-
nary disease or asthma, systemic lupus erythematosus,
rheumatoid arthritis, autoimmune hemolytic anemia,
chronic active hepatitis) [27], or due to intercurrent illness
such as HTLV-1 and HIV infection, organ transplantation,
Life cycle of Strongyloides stercoralis Figure 1
Life cycle of Strongyloides stercoralis. Complete life cycle of Strongyloides stercoralis with both parasitic and free living cycles 
along with the cycle leading to autoinfection and hyperinfection syndrome. The cycle involving the mechanism of autoinfection 
is shown on the right side of the figure with the cycle elucidating the concept of hyperinfection and disseminated infection on 
the left side of the figure (adapted from: Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for 
Disease Control & Prevention; Permission via phone taken from Ms. Melanie at (770) 488–4063).
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and other infectious diseases like kala-azar [28] can
increase the risk of hyperinfection syndrome in patients
with strongyloidiasis [1,4,21,29-36]. Hyperinfection syn-
drome is estimated to happen in 1.5 to 2.5% of the
patients with strongyloidiasis [37].
Hyperinfection syndrome is not exactly defined, but the
hallmark is an increase in the number of larvae in the
stool and/or sputum along with manifestations confined
to respiratory and gastrointestinal systems along with per-
itoneum [10]. The hyperinfection syndrome happens
from the enormous multiplication and migration of infec-
tive larvae especially in an immunosuppressed state. The
manifestations of hyperinfection syndrome are divided,
based on the system of origin, into intestinal and extrain-
testinal disease mainly involving the respiratory tract.
The intestinal manifestations include severe cramping
abdominal pain, watery diarrhea, weight loss, nausea,
vomiting and occasionally gastrointestinal bleeding [10].
Subacute intestinal obstruction can also be caused by
strongyloidiasis [38]. The extraintestinal manifestations
include mainly asthma-like symptoms such as cough and
wheezing, and others such as pneumonia and pulmonary
hemorrhage with diffuse bilateral infiltrates on the chest x
ray [1,10]. Rare conditions like eosinophilic pleural effu-
sions [39] and eosinophilic granulomatous enterocolitis
[40] have also been reported in strongyloidiasis.
4. Other manifestations (including disseminated infection)
Even though, most cases of strongyloidiasis are asympto-
matic or present with mild symptoms, fatal disseminated
infection with involvement of multiple organ systems
other than the respiratory and gastrointestinal systems as
in hyperinfection syndrome could also occur especially in
patients with immunosuppression from systemic steroids
[1,4]. Chronic infection and malnutrition also predispose
to systemic strongyloidiasis [19]. The mortality from dis-
seminated infection could be up to 87% [1,41,42]. The
high mortality rate associated with hyperinfection syn-
drome and disseminated disease is frequently due to sec-
ondary bacterial infections [43,44]. The disseminated
infection occurs when the larval load increases, leading to
involvement of multiple organs thereby leading to various
manifestations along with severe respiratory and gastroin-
testinal features as mentioned above [19].
The cutaneous manifestations that could occur from dis-
semination include widespread petechiae and purpura
[22,45]. Occasionally this may also present as a pruritic,
erythematous, morbiliform eruption [15], or as an
intensely itching prurigo [23]. One of the most important
and potentially fatal complications that can occur is gram
negative bacteremia mainly from pathogens such as Strep-
tococcus bovis [43],  Escherichia coli,  Streptococcus fecalis,
Klebsiella pneumoniae [1], or Enterobacter sp. [46] as they
become blood borne when the larvae penetrate the intes-
tine [31,43]. Involvement of the central nervous system
may lead to headache, altered mental state, seizures and
rarely coma [1]. Gram negative bacterial meningitis has
also been frequently reported, especially in association
immunosuppression [43,47-51].
Corticosteroids and Strongyloidiasis
Multiple case reports indicate a potential increase in the
frequency of fatal hyperinfection or disseminated infec-
tion with corticosteroid therapy in patients with asympto-
matic or mild strongyloidiasis [7,52-56]. Corticosteroids,
endogenous as well as exogenous, have been shown to
affect the immunity by increasing the apoptosis of Th2
cells, reducing the eosinophil count and inhibiting the
mast cell response there by leading to hyperinfection or
Table 2: Clinical Manifestations of Strongyloidiasis by Organ System
Organ System Symptoms Signs Investigation References
Skin Pruritis, Eruption Urticaria, Angioedema, Larva 
Currens, Eruption
CBC with differential counts
GI Abdominal pain, Diarrhea, Nausea, 
Vomiting
Weight loss, Malabsorption, 
Epigastric tenderness
Stools for parasites, Strongyloid 
antibody titer
[1]
Pulmonary Wheezing, Cough, Hemoptysis, 
Shortness of breath
Wheeze, Rales Chest X ray, Sputum culture, 
Sputum for parasites
CNS Headache, Altered mental state, 
Focal seizures, Coma
Meningeal signs, Disorientation Lumbar puncture and cultures [1]
Immune/Allergic Urticaria, Anaphylaxis Urticarial rash, Larva Currens rash CBC with differential counts [65]
Hematological Fever, Chills, Rigors Tachycardia, Bacteremia, 
Septicemia, Eosinophilia
Blood cultures, CBC with 
differential counts
[1]
Other (Rare) Peritonitis, Endocarditis, 
Eosinophilic pleural effusion, 
Eosinophilic granulomatous 
enterocolitis
[1]
[39]
[40]
GI, Gastrointestinal; CNS, Central Nervous System; CBC, Complete Blood Count;Clinical and Molecular Allergy 2006, 4:8 http://www.clinicalmolecularallergy.com/content/4/1/8
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disseminated infection [1]. It is also proposed that both
exogenous and endogenous corticosteroids increase
ecdysteroid like substances (naturally occurring sterols
with non-hormonal anabolic effects) in the body mainly
in the intestinal wall. These substances act as molting sig-
nals and lead to increased production of autoinfective
filariform larvae leading to hyperinfection and dissemi-
nated infection as shown in the Figure 2[41,57]. Siddiqui
et al., have demonstrated the presence of steroid receptor
on Strongyloides stercoralis, which could also play a role in
the pathogenesis of hyperinfection syndrome and more
systemic disseminated infection associated with corticos-
teroids, but this area needs further study [41].
Diagnostic aspects
The important conditions which can confuse the physi-
cians in the diagnosis of strongyloidiasis include other
nematode infections. Strongyloidiasis, especially the
hyperinfection syndrome and more systemic dissemi-
nated infection, can sometimes mimic pneumonia [58],
polyarteritis nodosa [59], malignant mediastinal neopla-
sia [60], eosinophilic folliculitis [61], relapse of lym-
phoma [62], primary intestinal lymphoma [38], flare up
of systemic lupus erythematosus [63], peptic ulcer disease
[64], and ulcerative colitis or crohn's disease [40,64].
Due to the asymptomatic nature of intestinal strongyloi-
diasis, and the risk for hyperinfection, screening of the
population in endemic areas especially before considering
Corticosteroids and strongyloid hyperinfection syndrome Figure 2
Corticosteroids and strongyloid hyperinfection syndrome. The pathophysiological pathway showing the mechanism of 
corticosteroids leading to strongyloid hyperinfection syndrome and disseminated infection. Corticosteroids along with cortisol 
act on specific receptors called glucocorticoid receptors (GCRs) available on CD4+ Th2 cell membrane causing apoptosis and 
thus T cell dysfunction. Corticosteroids also increase ecdysteroid like substances in the body which act as molting signals for 
eggs and rhabditiform larvae, leading to increased number of filariform larvae [41,57].
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immunosuppressive therapy is important. There is no one
ideal screening or diagnostic test, making strongyloidiasis
a difficult infection to detect in humans [18,65].
The most important laboratory finding seen in patients
with strongyloidiasis is eosinophilia [65]. Eosinophilia is
shown to be 93.5% sensitive with a specificity of 93.1% in
high risk populations [2]. But it is also shown that the
eosinophil count if used alone is not sufficiently sensitive
to screen for strongyloidiasis [18,66] especially in patients
with chronic infection who can have low or normal eosi-
nophil counts [65], in people returning from developing
countries [66], and in some cases of hyperinfection syn-
drome and disseminated strongyloidiasis. However,
increased peripheral eosinophilia in the case of hyperin-
fection syndrome could be considered as a good prognos-
tic factor [10]. Eosinophilia is not a cost effective strategy
compared to the stool examinations with agar plate cul-
ture method and serological testing in detecting strongy-
loides infection in humans [67].
Diagnosis of strongyloidiasis could be done by serological
methods especially in asymptomatic patients with eosi-
nophilia (as in the patient described in this report) or
mildly symptomatic patients. These serological tests are
also shown to be useful in the diagnosis of strongyloidia-
sis even in immunocompromised individuals [68]. The
serological methods determine the presence of strongy-
loid antibody in the serum of the human hosts. The anti-
body could be determined by the following methods: 1)
Enzyme-Linked Immuno-Sorbent Assay (ELISA) [69,70],
2) Gelatin Particle Indirect Agglutination (GPIA) [69],
and 3) Western Blot Analysis (WBA) [8].
Huaman et al., in their study showed that both ELISA and
GPIA are useful in the diagnosis of strongyloidiasis with
sensitivities of 74.1% and 98.2%, respectively and specif-
icity of 100% for both studies. As low titers of strongyloid-
specific antibodies are noted in hyperinfection along with
a low or normal eosinophil count, GPIA is more sensitive
than ELISA in detecting the specific immunoglobulin in
cases of chronic infection and hyperinfection [69]. New
strongyloides-specific antigens are being discovered that
may help in the immunodiagnosis of strongyloidiasis in a
more sensitive and effective way [71].
The diagnosis of strongyloidiasis can also be made very
reliably by observing strongyloid larvae in stool or spu-
tum specimens. But these tests are not accurate as there is
fluctuation in the rate of larval excretion especially in
stools [8] decreasing the efficacy and accuracy of these
tests [72]. Repeated multiple stool specimens should be
analyzed to increase the efficacy of the test in the presence
of strong suspicion of strongyloidiasis [2,8,73]. Sudharshi
et al., in their study have noted stool examinations by for-
malin-ether concentration method for larvae to be less
sensitive in detecting the disease when used alone, espe-
cially in non-endemic regions [18].
Microscopic examination of stool specimens is done for
strongyloid larvae. This can be done in the following dif-
ferent ways: 1) Simple direct smear with a sensitivity of 0–
52% [8], 2) Formalin-ether concentration method with a
sensitivity of 13–55% [8], 3) Harada-Mori filter paper cul-
ture method with almost equal sensitivity to the above 2
methods [74,75], and 4) Agar plate culture technique with
higher sensitivity of 78–100% [8]. Of all the mentioned
methods, multiple studies have shown detection of
strongyloides larvae in stool specimens is more effective
and accurate with agar plate culture technique [4,73-75].
Biopsy with duodenal intubation and Enterotest™ are
rarely used, though they have high sensitivity, because
they are very cumbersome [76].
Pathophysiological mechanisms and host 
defense pathways regulating Strongyloidiasis
Experiments on mice and other animal models have
yielded information about the immune mechanisms
against nematode parasites and they have also shown that
mechanisms differ depending on the host species and the
parasite strain used [77]. These experiments support the
theory that both T and B cell mediated immunity are
required in the immune response to Strongyloides stercora-
lis [78-80].
Increased serum IgE (Immunoglobulin E) levels, eosi-
nophilia in the peripheral blood, increased numbers of
mast cells in the intestine, and hyperplasia of goblet cells
of the intestine are the responses noted in the nematode
infections of the gastrointestinal tract [81-83]. Eosi-
nophils, intestinal mast cells and goblet cells, IgE, type 2
helper T (Th2) cells and cytokines such as IL-4 (Inter-
leukin-4), IL-5 (Interleukin-5), IL-6 (Interleukin-6), IL-9
(Interleukin-9), IL-10 (Interleukin-10), and IL-13 (Inter-
leukin-13) are shown to be the mediators of immunity
against Strongyloides stercoralis [1,83-91]. The various types
of defense mechanisms against strongyloides larvae are
shown in Table 3.
There are 2 broad types of defense mechanisms in the case
of S. stercoralis – mechanisms against the filariform larvae,
which infect the human host for the first time and mech-
anisms against the host adopted larvae that cause autoin-
fection. The following defense mechanisms may function
in one or both of the above types.
T cell mediated immunity, especially involving CD4+
cells, has been shown to be important in the defense
against Strongyloides stercoralis larvae using a rodent model
[92]. In humans, as the infection is more prevalent inClinical and Molecular Allergy 2006, 4:8 http://www.clinicalmolecularallergy.com/content/4/1/8
Page 8 of 13
(page number not for citation purposes)
hematological malignancies and HIV infected people, it is
proposed that T cell immunity involving CD4+ cells plays
a role in the defense against strongyloidiasis [11,12]. In a
study reported by Trajman et al., the detection of T cell-
dependent serum-specific IgA and IgE antibodies indi-
cates the importance of T cell immunity in S. stercoralis
infection [84]. It has been shown that contact with
immune cells is required for immunity against strongy-
loides larvae (as reported in a rodent model using the
human parasite, Strongyloides stercoralis) [93].
Type 2 T helper (Th2) cells that stimulate eosinophils, IgE
production, mast cells, and goblet cells by producing IL-4,
IL-5, IL-9 [91], IL-10 and IL-13, are important in the
defense against strongyloides infection [1,81,84,91,92].
This has been shown, for example, in people with co-
infection with HTLV-1 which decreases Th2 cell-mediated
immunity, thereby increasing the risk for hyperinfection
syndrome or disseminated infection [94].
In severe strongyloidiasis, no significant change in the T
cell numbers is noted compared with asymptomatic or
mildly symptomatic disease [95] indicating the impor-
tance of other immune mechanisms. It is also reported
that infected patients elicit a decreased lymphocyte blast-
ogenic response to larval Strongyloides stercoralis antigens
suggesting presence of factors in the serum of patients that
are inhibitory to the function of cell mediated immunity
[84,86].
Controversy exists over whether one cytokine is more
important than another in the resistance against nema-
todes even in animal studies. IL-3 (Interleukin-3) has
been shown in multiple previous studies as a potent mast
cell synthesis stimulator. But, Kobayashi et al., using a
rodent model showed Strongyloides venezuelensis can stim-
ulate mastocytosis without IL-3 indicating a role of other
mechanisms [90]. IL-4 is an important regulator of IgE
antibody production and mast cell activation [88]. Urban
et al., using an animal model with Heligmosomoides poly-
gyrus have shown that IL-4 is an important factor in the
defense against gastrointestinal nematode infections [88].
Watanabe et al., showed the importance of IL-4 in the
induction and maintenance of intestinal mast cells with
Strongyloides ratti in mice [81]. As no human studies are
available indicating the importance of IL-4, and with the
exact role of IL-4 in helminth infection being unknown, it
would be premature to consider IL-4 as an important fac-
tor in the defense against strongyloidiasis [91]. IL-5 is
important in differentiation, maturation and survival of
eosinophils [77] by regulating the eosinophil precursors
in the bone marrow [88]. Herbert et al., showed the pos-
sible roles played by IL-5 in innate as well as adaptive
immunity against human parasite larvae in mice, by
inducing eosinophil production during innate immunity
and IgM (Immunoglobulin M) production in the adaptive
immune response. Porto et al., in their effort to demon-
strate the effect of HTLV-1 in patients with strongyloidia-
sis, noticed increased IL-5 in patients with strongyloidiasis
[96]. These studies involving the human parasite-rodent
models and human parasite-humans indicate a very
important part played by IL-5 in the immunity against
strongyloides infection especially by inducing eosinophil
differentiation, maturation and survival.
Humoral immunity mainly includes the defense mecha-
nisms with the production of immunoglobulins by
plasma cells. Herbert et al., in their experiment with mice
using human parasites, showed that B cells play no part in
the defense against primary infection but play an impor-
tant role in subsequent challenge infections with a result-
ant increase in parasite specific immunoglobulin, mainly
IgM [78].
Immunoglobulins are shown to play an important role in
the defense against strongyloidiasis. Even though strongy-
loid-specific antibodies are noted in the infection, they do
not provide the required immunity without the help of
other defense mechanisms. There is increasing evidence
that IgE mediated activation of accessory cells can play an
important role in the resistance against parasitic infection
[82]. Even though IgE is increased in the helminth infec-
tions, most of that is non-specific and may block the
development of the host defense mechanism by saturat-
ing IgE receptors on effector cells [91]. Brigandi and cow-
orkers while experimenting with mice and Strongyloides
Table 3: Various Types of Immunity in Strongyloidiasis
Type of Immunity Mediators Reference
T Cell Mediated Immunity CD4+ Cells [11,12,92]
Th2 Cellular Immunity IL-4, IL-5 [77,81]
Humoral Immunity IgM, IgG, IgA, IgE [95,98]
Antibody Dependent Cellular Cytotoxicity IgM, IgG, Eosinophils, Neutrophils [91,98,99]
Mucosal Immunity Mast Cells, Goblet Cells [81,82,87]
Complement System Complement activation [99]
CD, Cluster Differentiation; Th2, Type 2 T Helper; IL, Interleukin; IgM, Immunoglobulin M; IgG, Immunoglobulin G; IgA, Immunoglobulin A; IgE, 
Immunoglobulin E;Clinical and Molecular Allergy 2006, 4:8 http://www.clinicalmolecularallergy.com/content/4/1/8
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stercoralis noticed IgE along with IgA to have no effect on
killing of infective larvae. In humans, IgE antibodies are
specifically formed against filariform larvae [97]. How-
ever, Badaro et al., showed that no correlation exists
between the total IgE, specific IgE and IgG (Immunoglob-
ulin G) antibody quantities and the clinical severity of
strongyloidiasis. As humans differ from rodents and
experimental models, IgE-mediated anti-parasite immu-
nity is controversial [91]. As there is an increase in IgE lev-
els in strongyloides infection both in human subjects with
the infection as well as in experimental models, it is likely
that IgE plays a pivotal role, but the exact nature of this
role is currently unclear. However, determination of IgE
levels with radioallergosorbant test (RAST) could be help-
ful in the immunological evaluation of the patient [97].
As it is shown in animal models, IgG and IgM can pas-
sively transfer immunity against human parasite larvae in
the presence of a well functioning complement system
and neutrophils [77,93,98,99]. In severe strongyloidiasis,
IgA (Immunoglobulin A), IgG and IgM levels were signif-
icantly lower compared with asymptomatic or mildly
symptomatic strongyloidiasis [95]. It is also shown, in
mouse model with the human parasite, host adopted or
autoinfective filariform larvae have different surface anti-
gens and IgM specific for primary infective filariform lar-
vae is not effective against autoinfective larvae [100]. Lack
of host response to autoinfective larvae along with lack of
specific IgM antibodies could play a role in autoinfection
and thus in hyperinfection syndrome and disseminated
infection.
Antibody Dependent Cellular Cytotoxicity (ADCC) is
proposed as one of the defense mechanisms against the
nematodes especially in rodent experiments involving
human parasite larvae with IgE activation of eosinophils
[1,91] as well as IgG activated ADCC involving neu-
trophils [98]. As shown in the experiments on mice with
Strongyloides stercoralis larvae, ADCC may play a role in the
immunity against live infective larvae but not against
injected larval antigens [98,101]. However, Kerepesi et al.,
with experiments on mice and human parasite larvae
indicated ADCC is not required for larval killing [102].
Insufficient and controversial results do not substantiate
the role played by ADCC in the immunity against strong-
yloides, requiring further research to demonstrate its
importance.
Eosinophils are bone marrow derived granulocytes which
can secrete highly toxic substances contained in their
granules in the wake of infections and allergic reactions
[82]. Eosinophil production is activated by IL-5 released
by the Th2 cells and in turn eosinophils also release lym-
phocyte active cytokines that can stimulate and affect the
functioning of lymphocytes [82,103]. In experimental
studies using mice and human parasite larvae, an increase
in eosinophils is seen with parasite killing in nematode
infections [93,104]. Eosinophils seem to be directly
involved in the destruction of helminths and their migrat-
ing larvae as they penetrate the intestinal mucosa [83,91]
as shown in the animal studies, especially in mice in the
presence of specific antibodies [82,91]. Though eosi-
nophils can cause destruction of helminth larvae, espe-
cially host-adopted filariform larvae [104], it is not
sufficient for complete protection [91]. In humans, their
role in the defense against S. stercoralis is controversial.
Even though eosinophils are noted to be important in
defense against Strongyloides stercoralis, significantly lower
eosinophil counts are noted in severe strongyloidiasis
[95] indicating a possibility of suppression of eosinophils
especially in disseminated infections. Neutrophils are
important in immunity against infective larvae of Strongy-
loides stercoralis in mice [98,99] which could also play a
role in human strongyloidiasis. They are shown to have a
controversial effect through the ADCC mechanism with
the help of IgG as mentioned earlier.
All nematode infections elicit the same intestinal phe-
nomena with different effector mechanisms [81,91].
Strongyloides infections are difficult to eradicate com-
pletely mainly because of autoinfection. As this nematode
resides in the small intestine [1,10] of the human beings,
local mucosal immunity along with inflammatory
changes may play a role in their eradication [87]. Many
studies are done on mice to evaluate the mucosal
responses to gastrointestinal nematode infections. There
are different mechanisms in which the local mucosal
immunity defends against the infection manifesting in
different forms like expulsion of the adult worms,
decrease in the length of the worms, reduction in fecun-
dity of the female worms, and failure of infective larvae to
establish [87]. The above said mucosal defense mecha-
nisms are mediated by both humoral and cell mediated
immunity.
Studies with animal models and Strongyloides ratti showed
the important role played by goblet cells in the expulsion
of the parasite from the GI tract [81]. These goblet cells
were induced by IL-13 secreted by Th2 cells [81]. Intestinal
mastocytosis, induced by IL-3 [90], is observed in many
nematode infections. Mast cells are also shown to play an
important role in the defense against parasite infestations
[82] and are considered as the effector cells against Strong-
yloides species even in humans [90]. Experiments on mice
with Strongyloides species have shown the importance of
intestinal mastocytosis in the expulsion of the worm from
the gastrointestinal tract.Clinical and Molecular Allergy 2006, 4:8 http://www.clinicalmolecularallergy.com/content/4/1/8
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Trajman et al., in their study, have noted that intestinal
response in the form of expulsion is seen in rodent exper-
iments and could not be confirmed in human beings. No
change in the jejunal morphology, different T cell subset
numbers, mast cells, eosinophils and goblet cells were
noted along with lack of cell activation in the mucosa as
shown by the absence of CD25+ cells. However, they
noted a decrease in the number of mature macrophages
and dividing enterocytes in the crypts of the intestinal wall
[84]. Absence of immune response might be the reason
for preservation of architecture of the mucosa and absence
of immune mediated diarrhea in Strongyloides stercoralis
infection. This indicates the controversial role of the
mucosal immunity played against strongyloides infec-
tions necessitating further studies especially involving
human subjects.
Activation of both classical and alternate pathway of the
complement system [102,105] with chemoattraction and
binding of the granulocytes to the infective larvae has also
been shown to play a role in the immunity against S. ster-
coralis in mice [99,102]. Machado et al., with their experi-
ment on mice have indicated the potential role played by
the leukotrienes as immunostimulants against strongy-
loides [106]. But the specific role of complement and leu-
kotrienes in strongyloides infections is not proven even in
experimental animals.
Management
Albendazole, mebendazole, thiabendazole and ivermec-
tin have shown to be effective on Strongyloides stercoralis
[107-109]. Recently, there has been a change in the treat-
ment of strongyloidiasis with more studies showing iver-
mectin as the drug of choice. In a randomized control trial
done by Gann et al., comparing ivermectin with thiaben-
dazole, the investigators showed that one dose of ivermec-
tin is as effective as prolonged thiabendazole in the
treatment of strongyloidiasis with less adverse side effects
[107]. Ivermectin is shown to be very effective in the treat-
ment of strongyloidiasis [109] as well as in the treatment
of hyperinfection syndrome with predisposing conditions
like AIDS (Acquired Immunodeficiency Syndrome) [33].
Treatment of strongyloidiasis has been shown to improve
the cutaneous manifestations [25] as well as asthma-like
symptoms associated with the nematode [110].
In Strongyloides stercoralis-infected patients presenting with
asthma-like symptoms, physicians should be cautious in
using leukotriene synthesis inhibitors. The use of leukot-
riene synthesis inhibitors may worsen the infection as leu-
kotrienes are shown to play a potential role in the
immunity against strongyloides infection in murine ani-
mal models [106] and possibly in human subjects. More
research is needed in this aspect before limiting the use of
leukotriene synthesis inhibitors.
Relapses, especially involving gastrointestinal tract, were
noted even after treatment of strongyloidiasis. For the
chronicity of the infection and possibility of occurrence of
dangerous exacerbations, diagnostic surveillance is rec-
ommended to prevent the occurrence of fatal hyperinfec-
tion [65]. The surveillance could be done in the form of
repeat eosinophil counts along with serological surveil-
lance with serial antibody titers and multiple stool speci-
mens for larvae.
The efficacy of the treatment depends on many factors like
immunodeficiency, co-infection with HTLV-1, use of cor-
ticosteroids and presence of bowel ileus that can decrease
the efficacy of the drugs used in the treatment of strongy-
loidiasis [19,94]. Monitoring the response to treatment
could be very difficult with detection of strongyloid larvae
in the stool specimen because of the inconsistent shed-
ding of the larvae [72].
Loutfy et al., in their study have suggested that serological
tests mainly EIA with serial eosinophil counts could be
used to monitor the response to the treatment [76]. In a
study involving 3 patients with strongyloidiasis, serial
total IgE levels decreased after effective treatment indicat-
ing a possibility of using serial total IgE levels in monitor-
ing the response to treatment [111]. As no prospective
studies were done in this direction, it would be very diffi-
cult to determine which test would be the test-of-cure for
strongyloidiasis [76]. Failure to respond to treatment or
recurrence of hyperinfection syndrome is an indication to
look for latent or asymptomatic HTLV-1 infection [, ].
Personal hygienic measures like proper protection of skin
to prevent contact with infected soil, community level
hygienic measures like proper disposal of human excreta,
community education about protective and hygienic
measures, and prompt treatment of diagnosed cases
would help in the prevention of the disease [44].
Vaccines, which are effective against infective stage filari-
form larvae could be a possibility based on the experi-
mental evidence in mice, especially if composed of
multiple antigens [98,99,102,104]. Further studies
mainly involving voluntary human subjects are required
to confirm this possibility.
Conclusion
Strongyloidiasis is a nematode infection with a tendency
to become chronic with fatal complications of hyperinfec-
tion syndrome and disseminated infection along with a
host of other potential complications like gram-negative
bacteremia and meningitis. As the infection is mostly
chronic and asymptomatic, and there is no specific ideal
test to diagnose the disease, it still tends to be a diagnosti-
cally elusive disease even in the present era.Clinical and Molecular Allergy 2006, 4:8 http://www.clinicalmolecularallergy.com/content/4/1/8
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Non-endemic regions of the world have endemic pockets
for strongyloidiasis, like rural Tennessee and Kentucky in
the USA, making the disease more important especially in
view of potentially fatal hyperinfection syndrome and dis-
seminated infection. As most cases of hyperinfection syn-
drome and disseminated strongyloidiasis happen in
immunocompromised individuals, especially those who
are taking systemic steroids, physicians in the endemic
areas should be aware of the bizarre manifestations of the
disease that can mimic other diseases leading to misdiag-
nosis and medical errors.
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